ENDRA Life Sciences Inc. Income Statement
NDRA|4 years of annual SEC 10-K data (FY2017-FY2020)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
ENDRA Life Sciences Inc. reported $0 in revenue and $12M in net loss for FY2020. Revenue has declined at a 86.7% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|
| Revenue | $0 | $6.2K | $351.6K | $351.6K |
| Cost of Revenue | $0 | $0 | $172.8K | $172.8K |
| Gross Profit | $0 | $6.2K | $178.8K | $178.8K |
| SG&A Expense | $5.0M | $3.8M | $2.8M | $2.8M |
| R&D Expense | $5.9M | $4.7M | $1.9M | $1.9M |
| Operating Income | -$11.5M | -$9.0M | -$4.6M | -$4.6M |
| Interest Expense | - | - | $1.5K | $42.6K |
| Income Tax | $0 | $0 | $0 | $0 |
| Net Income | -$11.7M | -$9.8M | -$5.4M | -$5.4M |
| EPS (Diluted) | -$2.34 | -$2.17 | -$1.95 | -$3.84 |
| Shares Outstanding | 8.4M | 7.4M | 3.9M | 723.3K |
| Gross Margin | - | 100.0% | 50.9% | 50.9% |
| Operating Margin | - | -146080.5% | -1315.6% | -1315.6% |
| Profit Margin | - | -158669.6% | -1529.2% | -1529.2% |